CA2308768A1 - 125 proteines secretees humaines - Google Patents
125 proteines secretees humaines Download PDFInfo
- Publication number
- CA2308768A1 CA2308768A1 CA002308768A CA2308768A CA2308768A1 CA 2308768 A1 CA2308768 A1 CA 2308768A1 CA 002308768 A CA002308768 A CA 002308768A CA 2308768 A CA2308768 A CA 2308768A CA 2308768 A1 CA2308768 A1 CA 2308768A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- gene
- tissues
- polynucleotides
- polypeptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 679
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 234
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 14
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 12
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 12
- 239000013598 vector Substances 0.000 claims abstract description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 380
- 102000040430 polynucleotide Human genes 0.000 claims description 380
- 239000002157 polynucleotide Substances 0.000 claims description 379
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 335
- 229920001184 polypeptide Polymers 0.000 claims description 333
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 333
- 230000014509 gene expression Effects 0.000 claims description 220
- 125000003729 nucleotide group Chemical group 0.000 claims description 126
- 239000000047 product Substances 0.000 claims description 118
- 239000002773 nucleotide Substances 0.000 claims description 68
- 239000012472 biological sample Substances 0.000 claims description 59
- 239000002299 complementary DNA Substances 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 10
- 230000004071 biological effect Effects 0.000 claims description 9
- 230000001575 pathological effect Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 238000004166 bioassay Methods 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 238000002405 diagnostic procedure Methods 0.000 abstract description 2
- 238000010188 recombinant method Methods 0.000 abstract description 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 567
- 210000004027 cell Anatomy 0.000 description 365
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 346
- 208000035475 disorder Diseases 0.000 description 260
- 235000018102 proteins Nutrition 0.000 description 224
- 238000011282 treatment Methods 0.000 description 124
- 238000003745 diagnosis Methods 0.000 description 120
- 210000001124 body fluid Anatomy 0.000 description 115
- 239000000523 sample Substances 0.000 description 115
- 201000010099 disease Diseases 0.000 description 85
- 238000009826 distribution Methods 0.000 description 71
- 239000003153 chemical reaction reagent Substances 0.000 description 62
- 239000012530 fluid Substances 0.000 description 59
- 210000002381 plasma Anatomy 0.000 description 58
- 210000002966 serum Anatomy 0.000 description 58
- 210000002700 urine Anatomy 0.000 description 58
- 230000001900 immune effect Effects 0.000 description 57
- 210000002751 lymph Anatomy 0.000 description 57
- 210000001179 synovial fluid Anatomy 0.000 description 57
- 230000004069 differentiation Effects 0.000 description 51
- 230000035755 proliferation Effects 0.000 description 51
- 210000004556 brain Anatomy 0.000 description 48
- 208000026278 immune system disease Diseases 0.000 description 48
- 238000009169 immunotherapy Methods 0.000 description 48
- 239000000439 tumor marker Substances 0.000 description 47
- 206010028980 Neoplasm Diseases 0.000 description 45
- 210000000987 immune system Anatomy 0.000 description 39
- 238000001514 detection method Methods 0.000 description 36
- 210000000349 chromosome Anatomy 0.000 description 34
- 210000000130 stem cell Anatomy 0.000 description 31
- 210000001744 T-lymphocyte Anatomy 0.000 description 30
- 201000011510 cancer Diseases 0.000 description 30
- 208000032839 leukemia Diseases 0.000 description 27
- 230000001850 reproductive effect Effects 0.000 description 27
- 230000003394 haemopoietic effect Effects 0.000 description 25
- 210000000440 neutrophil Anatomy 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 208000018706 hematopoietic system disease Diseases 0.000 description 23
- 210000004185 liver Anatomy 0.000 description 23
- 206010039073 rheumatoid arthritis Diseases 0.000 description 22
- 206010003246 arthritis Diseases 0.000 description 21
- 208000029462 Immunodeficiency disease Diseases 0.000 description 20
- 208000024827 Alzheimer disease Diseases 0.000 description 19
- 230000004913 activation Effects 0.000 description 19
- 230000008569 process Effects 0.000 description 19
- 201000000980 schizophrenia Diseases 0.000 description 19
- 206010061218 Inflammation Diseases 0.000 description 18
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- 208000006673 asthma Diseases 0.000 description 18
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 18
- 230000004054 inflammatory process Effects 0.000 description 18
- 239000003550 marker Substances 0.000 description 18
- 206010026749 Mania Diseases 0.000 description 17
- 206010033864 Paranoia Diseases 0.000 description 17
- 208000027099 Paranoid disease Diseases 0.000 description 17
- 208000018737 Parkinson disease Diseases 0.000 description 17
- 230000028993 immune response Effects 0.000 description 17
- 208000015122 neurodegenerative disease Diseases 0.000 description 17
- 206010012289 Dementia Diseases 0.000 description 16
- 206010020751 Hypersensitivity Diseases 0.000 description 16
- 210000000952 spleen Anatomy 0.000 description 16
- 238000013519 translation Methods 0.000 description 16
- 210000000481 breast Anatomy 0.000 description 15
- 230000001537 neural effect Effects 0.000 description 15
- 230000019491 signal transduction Effects 0.000 description 15
- 208000030507 AIDS Diseases 0.000 description 14
- 208000023105 Huntington disease Diseases 0.000 description 14
- 201000004681 Psoriasis Diseases 0.000 description 14
- 206010040047 Sepsis Diseases 0.000 description 14
- 210000003169 central nervous system Anatomy 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 230000001605 fetal effect Effects 0.000 description 14
- 208000030159 metabolic disease Diseases 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 14
- 208000023275 Autoimmune disease Diseases 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 13
- 230000004770 neurodegeneration Effects 0.000 description 13
- 208000002874 Acne Vulgaris Diseases 0.000 description 12
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 12
- 206010039710 Scleroderma Diseases 0.000 description 12
- 206010000496 acne Diseases 0.000 description 12
- 230000030741 antigen processing and presentation Effects 0.000 description 12
- 230000024245 cell differentiation Effects 0.000 description 12
- 230000036737 immune function Effects 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 230000024833 regulation of cytokine production Effects 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 208000004235 neutropenia Diseases 0.000 description 11
- 210000000056 organ Anatomy 0.000 description 11
- 230000002062 proliferating effect Effects 0.000 description 11
- 208000016192 Demyelinating disease Diseases 0.000 description 10
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 10
- 230000003542 behavioural effect Effects 0.000 description 10
- 230000033228 biological regulation Effects 0.000 description 10
- 208000014674 injury Diseases 0.000 description 10
- 230000002503 metabolic effect Effects 0.000 description 10
- 208000019906 panic disease Diseases 0.000 description 10
- 206010000117 Abnormal behaviour Diseases 0.000 description 9
- 208000009329 Graft vs Host Disease Diseases 0.000 description 9
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 206010025135 lupus erythematosus Diseases 0.000 description 9
- 208000012239 Developmental disease Diseases 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 description 8
- 206010042971 T-cell lymphoma Diseases 0.000 description 8
- 210000004381 amniotic fluid Anatomy 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 230000001363 autoimmune Effects 0.000 description 8
- 230000003412 degenerative effect Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000008105 immune reaction Effects 0.000 description 8
- 208000000509 infertility Diseases 0.000 description 8
- 230000036512 infertility Effects 0.000 description 8
- 231100000535 infertility Toxicity 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 210000001550 testis Anatomy 0.000 description 8
- 206010003805 Autism Diseases 0.000 description 7
- 208000020706 Autistic disease Diseases 0.000 description 7
- 208000003174 Brain Neoplasms Diseases 0.000 description 7
- 206010012305 Demyelination Diseases 0.000 description 7
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 7
- 206010018691 Granuloma Diseases 0.000 description 7
- 206010061598 Immunodeficiency Diseases 0.000 description 7
- 206010029379 Neutrophilia Diseases 0.000 description 7
- 208000028017 Psychotic disease Diseases 0.000 description 7
- 208000021386 Sjogren Syndrome Diseases 0.000 description 7
- 230000010782 T cell mediated cytotoxicity Effects 0.000 description 7
- 208000000323 Tourette Syndrome Diseases 0.000 description 7
- 208000016620 Tourette disease Diseases 0.000 description 7
- 230000003213 activating effect Effects 0.000 description 7
- 230000007815 allergy Effects 0.000 description 7
- 230000005784 autoimmunity Effects 0.000 description 7
- 230000006399 behavior Effects 0.000 description 7
- 210000005013 brain tissue Anatomy 0.000 description 7
- 208000015114 central nervous system disease Diseases 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 7
- 210000001612 chondrocyte Anatomy 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 210000001723 extracellular space Anatomy 0.000 description 7
- 208000007475 hemolytic anemia Diseases 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 230000009610 hypersensitivity Effects 0.000 description 7
- 230000007813 immunodeficiency Effects 0.000 description 7
- 201000003723 learning disability Diseases 0.000 description 7
- 208000019423 liver disease Diseases 0.000 description 7
- 230000003387 muscular Effects 0.000 description 7
- 208000020016 psychiatric disease Diseases 0.000 description 7
- 230000007958 sleep Effects 0.000 description 7
- 208000019116 sleep disease Diseases 0.000 description 7
- 208000037816 tissue injury Diseases 0.000 description 7
- 201000004624 Dermatitis Diseases 0.000 description 6
- 208000007466 Male Infertility Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 201000007201 aphasia Diseases 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 210000002798 bone marrow cell Anatomy 0.000 description 6
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000000066 myeloid cell Anatomy 0.000 description 6
- 230000009826 neoplastic cell growth Effects 0.000 description 6
- 210000003463 organelle Anatomy 0.000 description 6
- 210000002826 placenta Anatomy 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 210000001258 synovial membrane Anatomy 0.000 description 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000008733 trauma Effects 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000010322 bone marrow transplantation Methods 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000019771 cognition Effects 0.000 description 5
- 230000002124 endocrine Effects 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 231100000283 hepatitis Toxicity 0.000 description 5
- 208000006359 hepatoblastoma Diseases 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 208000003669 immune deficiency disease Diseases 0.000 description 5
- 230000037451 immune surveillance Effects 0.000 description 5
- 230000013016 learning Effects 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000006576 neuronal survival Effects 0.000 description 5
- 210000002741 palatine tonsil Anatomy 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 210000001525 retina Anatomy 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 210000000225 synapse Anatomy 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 4
- 208000017701 Endocrine disease Diseases 0.000 description 4
- 102100028701 General vesicular transport factor p115 Human genes 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 206010023126 Jaundice Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 206010037549 Purpura Diseases 0.000 description 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 description 4
- 206010057644 Testis cancer Diseases 0.000 description 4
- 208000002474 Tinea Diseases 0.000 description 4
- 206010052779 Transplant rejections Diseases 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000000748 cardiovascular system Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 201000001981 dermatomyositis Diseases 0.000 description 4
- 230000028023 exocytosis Effects 0.000 description 4
- 208000024908 graft versus host disease Diseases 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000011275 oncology therapy Methods 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 230000007261 regionalization Effects 0.000 description 4
- 210000004739 secretory vesicle Anatomy 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 201000003120 testicular cancer Diseases 0.000 description 4
- 108010037501 vesicular transport factor p115 Proteins 0.000 description 4
- 206010002329 Aneurysm Diseases 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010013883 Dwarfism Diseases 0.000 description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 201000009906 Meningitis Diseases 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 206010058571 Spinal cord infarction Diseases 0.000 description 3
- 208000036982 Spinal cord ischaemia Diseases 0.000 description 3
- 208000000491 Tendinopathy Diseases 0.000 description 3
- 206010043255 Tendonitis Diseases 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 3
- 208000017504 atelosteogenesis type II Diseases 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000003185 calcium uptake Effects 0.000 description 3
- 208000017568 chondrodysplasia Diseases 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000013020 embryo development Effects 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 210000004696 endometrium Anatomy 0.000 description 3
- 238000011124 ex vivo culture Methods 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 210000005153 frontal cortex Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000036244 malformation Effects 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 208000015625 metaphyseal chondrodysplasia Diseases 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 230000004031 neuronal differentiation Effects 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 208000027232 peripheral nervous system disease Diseases 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 210000004994 reproductive system Anatomy 0.000 description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000020431 spinal cord injury Diseases 0.000 description 3
- 201000003504 spondyloepiphyseal dysplasia congenita Diseases 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 230000005062 synaptic transmission Effects 0.000 description 3
- 201000004415 tendinitis Diseases 0.000 description 3
- 230000002381 testicular Effects 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 206010007882 Cellulitis Diseases 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 208000027205 Congenital disease Diseases 0.000 description 2
- 206010067248 Congenital naevus Diseases 0.000 description 2
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 102000011426 Enoyl-CoA hydratase Human genes 0.000 description 2
- 108010023922 Enoyl-CoA hydratase Proteins 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 208000004898 Herpes Labialis Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000980823 Homo sapiens Leukocyte surface antigen CD53 Proteins 0.000 description 2
- 206010021531 Impetigo Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 208000002260 Keloid Diseases 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 208000000185 Localized scleroderma Diseases 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 206010027627 Miliaria Diseases 0.000 description 2
- 201000009139 Mongolian Spot Diseases 0.000 description 2
- 206010027982 Morphoea Diseases 0.000 description 2
- 101100436270 Mus musculus Astn1 gene Proteins 0.000 description 2
- 101000931108 Mus musculus DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 2
- 208000007256 Nevus Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- 206010033661 Pancytopenia Diseases 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 241000721454 Pemphigus Species 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 241001672981 Purpura Species 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 206010040925 Skin striae Diseases 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 102000018509 Sulfate Transporters Human genes 0.000 description 2
- 108010091582 Sulfate Transporters Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 208000037913 T-cell disorder Diseases 0.000 description 2
- 241000130764 Tinea Species 0.000 description 2
- 241000893966 Trichophyton verrucosum Species 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 206010048211 Xanthelasma Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 230000005742 definitive hemopoiesis Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000009429 distress Effects 0.000 description 2
- 230000007368 endocrine function Effects 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 210000005095 gastrointestinal system Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 201000011066 hemangioma Diseases 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 210000001117 keloid Anatomy 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000003580 lung surfactant Substances 0.000 description 2
- 239000002583 male contraceptive agent Substances 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 201000004169 miliaria rubra Diseases 0.000 description 2
- 208000008588 molluscum contagiosum Diseases 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 206010028537 myelofibrosis Diseases 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- 230000017511 neuron migration Effects 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 206010034754 petechiae Diseases 0.000 description 2
- 230000036211 photosensitivity Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 235000020043 port wine Nutrition 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 208000003476 primary myelofibrosis Diseases 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 208000013223 septicemia Diseases 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000018556 stomach disease Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150098072 20 gene Proteins 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 102100027708 Astrotactin-1 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000006992 Color Vision Defects Diseases 0.000 description 1
- 208000026372 Congenital cystic kidney disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010050702 Crush syndrome Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000007984 Female Infertility Diseases 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102100040977 Follitropin subunit beta Human genes 0.000 description 1
- 101710203050 Follitropin subunit beta Proteins 0.000 description 1
- 208000007522 Fused Kidney Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 101000936741 Homo sapiens Astrotactin-1 Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- 206010021067 Hypopituitarism Diseases 0.000 description 1
- 206010021928 Infertility female Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000010728 Meckel diverticulum Diseases 0.000 description 1
- 108010037255 Member 7 Tumor Necrosis Factor Receptor Superfamily Proteins 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 101710124239 Poly(A) polymerase Proteins 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 208000008718 Pyuria Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 206010068033 Renal fusion anomaly Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 101150010882 S gene Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 206010066969 Vitello-intestinal duct remnant Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000037086 body physiology Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 201000009613 breast lymphoma Diseases 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 201000007254 color blindness Diseases 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 208000023965 endometrium neoplasm Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960000900 human factor viii Drugs 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 201000006318 hyperopia Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 230000005830 kidney abnormality Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000004995 male reproductive system Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 230000007372 neural signaling Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940052586 pro 12 Drugs 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 201000010384 renal tubular acidosis Diseases 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 210000003956 transport vesicle Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne de nouvelles protéines sécrétées humaines et des acides nucléiques isolés contenant les régions codantes des gènes codant pour ces protéines. L'invention concerne en outre des vecteurs, des cellules hôtes, des anticorps et des techniques recombinantes permettant de produire ces protéines sécrétées humaines. L'invention concerne en outre des méthodes diagnostiques et thérapeutiques utiles dans le diagnostic et le traitement des troubles associés à ces nouvelles protéines sécrétées humaines.
Applications Claiming Priority (29)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6490097P | 1997-11-07 | 1997-11-07 | |
| US6490897P | 1997-11-07 | 1997-11-07 | |
| US6498897P | 1997-11-07 | 1997-11-07 | |
| US6491297P | 1997-11-07 | 1997-11-07 | |
| US6491197P | 1997-11-07 | 1997-11-07 | |
| US6498597P | 1997-11-07 | 1997-11-07 | |
| US6498397P | 1997-11-07 | 1997-11-07 | |
| US6498797P | 1997-11-07 | 1997-11-07 | |
| US6498497P | 1997-11-07 | 1997-11-07 | |
| US60/064,911 | 1997-11-07 | ||
| US60/064,912 | 1997-11-07 | ||
| US60/064,983 | 1997-11-07 | ||
| US60/064,985 | 1997-11-07 | ||
| US60/064,988 | 1997-11-07 | ||
| US60/064,908 | 1997-11-07 | ||
| US60/064,900 | 1997-11-07 | ||
| US60/064,987 | 1997-11-07 | ||
| US60/064,984 | 1997-11-07 | ||
| US6609597P | 1997-11-17 | 1997-11-17 | |
| US6609497P | 1997-11-17 | 1997-11-17 | |
| US6610097P | 1997-11-17 | 1997-11-17 | |
| US6608997P | 1997-11-17 | 1997-11-17 | |
| US6609097P | 1997-11-17 | 1997-11-17 | |
| US60/066,090 | 1997-11-17 | ||
| US60/066,089 | 1997-11-17 | ||
| US60/066,095 | 1997-11-17 | ||
| US60/066,094 | 1997-11-17 | ||
| US60/066,100 | 1997-11-17 | ||
| PCT/US1998/023435 WO1999024836A1 (fr) | 1997-11-07 | 1998-11-04 | 125 proteines secretees humaines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2308768A1 true CA2308768A1 (fr) | 1999-05-20 |
Family
ID=27585021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002308768A Abandoned CA2308768A1 (fr) | 1997-11-07 | 1998-11-04 | 125 proteines secretees humaines |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1032838A4 (fr) |
| JP (1) | JP2003525566A (fr) |
| CA (1) | CA2308768A1 (fr) |
| WO (1) | WO1999024836A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7005295B1 (en) | 1997-04-16 | 2006-02-28 | Wyeth | β-amyloid peptide-binding proteins and polynucleotides encoding the same |
| US6787319B2 (en) | 1997-04-16 | 2004-09-07 | American Home Products Corp. | β-amyloid peptide-binding proteins and polynucleotides encoding the same |
| US7160985B2 (en) * | 1997-10-29 | 2007-01-09 | Genentech, Inc. | Pro180 polypeptide |
| NZ510997A (en) * | 1998-10-13 | 2004-01-30 | Wyeth Corp | G-protein-coupled receptor-like proteins, polynucleotides encoded by them, and methods of using same |
| WO2000071581A1 (fr) * | 1999-05-20 | 2000-11-30 | Takeda Chemical Industries, Ltd. | Nouveau polypeptide |
| FR2795075A1 (fr) * | 1999-06-18 | 2000-12-22 | Ass Pour Le Dev De La Rech En | CLONAGE, EXPRESSION ET CARACTERISATION D'UN ADNc CODANT POUR UN RECEPTEUR GAMMA-HYDROXYBUTYRATE (GHB) DE CERVEAU DE RAT |
| AU6181300A (en) * | 1999-07-29 | 2001-02-19 | Helix Research Institute | Liver cancer-associated genes |
| CA2380355A1 (fr) * | 1999-09-01 | 2001-03-08 | Genentech, Inc. | Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci |
| AU2001241735A1 (en) * | 2000-02-25 | 2001-09-03 | Pharmacia And Upjohn Company | Novel g protein-coupled receptors |
| CA2427010A1 (fr) * | 2000-10-27 | 2002-05-23 | Incyte Genomics, Inc. | Transporteurs et canaux a ions |
| US6783969B1 (en) * | 2001-03-05 | 2004-08-31 | Nuvelo, Inc. | Cathepsin V-like polypeptides |
| US8614169B2 (en) * | 2001-12-04 | 2013-12-24 | Wayne State University | Neoepitope detection of disease using protein arrays |
| EP1463818A2 (fr) * | 2001-12-14 | 2004-10-06 | Incyte Genomics, Inc. | Transporteurs et canaux ioniques |
| WO2003095622A2 (fr) * | 2002-05-10 | 2003-11-20 | Incyte Corporation | Proteines associees a la croissance, la differentiation et la mort cellulaires |
| CA2676790A1 (fr) * | 2007-02-22 | 2008-08-28 | Genentech, Inc. | Methode de detection d'une maladie intestinale inflammatoire |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5580753A (en) * | 1989-05-23 | 1996-12-03 | Ludwig Institute For Cancer Research | DNA encoding the human cytokine, interleukin-9 |
| EP0871702B1 (fr) * | 1994-12-06 | 2005-05-25 | Immunex Corporation | Cytokine designee par lerk-7 |
| US5707829A (en) * | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
-
1998
- 1998-11-04 CA CA002308768A patent/CA2308768A1/fr not_active Abandoned
- 1998-11-04 WO PCT/US1998/023435 patent/WO1999024836A1/fr not_active Ceased
- 1998-11-04 JP JP2000519788A patent/JP2003525566A/ja not_active Withdrawn
- 1998-11-04 EP EP98956533A patent/EP1032838A4/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999024836A1 (fr) | 1999-05-20 |
| JP2003525566A (ja) | 2003-09-02 |
| EP1032838A4 (fr) | 2003-01-29 |
| EP1032838A1 (fr) | 2000-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2339301A1 (fr) | Acides nucleiques et polypeptides relatifs au hdpbo81 | |
| US20200254058A1 (en) | Therapeutic trem-1 peptides | |
| CA2308768A1 (fr) | 125 proteines secretees humaines | |
| Van Ostade et al. | Structure-activity studies of human tumour necrosis factors | |
| JP6466833B2 (ja) | 抗炎症活性を有するペプチド、及びそれを含む組成物 | |
| JP6352911B2 (ja) | 抗炎症活性を有するペプチド、及びそれを含む組成物 | |
| KR101997757B1 (ko) | 악액질 예방 또는 치료용 조성물 | |
| EP2987497B1 (fr) | Composition destinée à traiter et à prévenir des lésions ischémiques | |
| KR102024186B1 (ko) | 톨-유사 수용체(tlr) 억제를 위한 펩타이드 및 이를 포함하는 약학적 조성물 | |
| CA2283299A1 (fr) | 186 nouvelles proteines secretees | |
| US20180207241A1 (en) | Peptide having fibrosis inhibitory activity and composition containing same | |
| CA2331154A1 (fr) | Polypeptides presentant une sequence distincte comprenant une sous-unite de facteur de croissance insulinomimetique labile en milieu acide | |
| KR20170033372A (ko) | 인터루킨-23 수용체의 경구용 펩티드 억제제 및 염증성 장 질환을 치료하기 위한 그의 용도 | |
| JPH06508742A (ja) | 組換えトロンビンレセプターおよびそれに関連した薬剤 | |
| JP2002533058A (ja) | ９７個のヒト分泌タンパク質 | |
| TW202000686A (zh) | 補體抑制素(compstatin)類似物及其醫藥用途 | |
| KR20030032940A (ko) | 신규 화합물 | |
| JP2002501738A (ja) | ６７個のヒト分泌タンパク質 | |
| CA2431374A1 (fr) | Nouveaux facteurs de croissance du fibroblaste | |
| CA2372926A1 (fr) | 143 proteines humaines secretees | |
| JP2002520050A (ja) | ７１個のヒト分泌タンパク質 | |
| CA2307320A1 (fr) | 148 proteines humaines secretees | |
| EP1465927B1 (fr) | Anticorps contre bag3 a utiliser dans la recherche, le diagnostic et le traitement de maladies impliquant la mort cellulaire | |
| US8071716B2 (en) | Thymus-specific protein | |
| TWI634210B (zh) | 抑制熱休克蛋白質表現之胜肽及包含其之組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |